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Abstract
Background: Altered lipid profile, and in particular low HDL and high triglyceride (TG) plasma levels, are within the
major determinants of cardiovascular diseases. The identification of quantitative trait loci (QTL) affecting these lipid
levels is a relevant issue for predictive purposes. The WWOX gene has been recently associated with HDL levels.
This gene is located at chromosome 16q23, a region previously linked to familial combined hyperlipidemia (FCHL)
and HDL. Our objective is to perform a genetic association analysis at the WWOX gene region with HDL, TG and
TG/HDL ratio.
Methods: A quantitative association analysis performed in 801 individuals selected from the Spanish general
population.
Results: For HDL levels, two regions of intron 8 display clustering of positive signals (p < 0.05) but none of them
was associated in the haplotypic analysis (0.07 ≤ p ≤ 0.165). For TG levels not only intron 8 but also a 27 kb region
spanning from the promoter region to intron 4 are associated in this study. For the TG/HDL genetic association
analysis, positive signals are coincident with those of the isolated traits. Interestingly, haplotypic analysis at the
5’ region showed that variation in this region modified both HDL and TG levels, especially the latter (p = 0.003).
Conclusions: Our results suggest that WWOX is a QTL for both TG and HDL.
Background
Altered lipid profile is one of the major determinants of
cardiovascular disease, which is the first cause of death
in the developed countries. Unhealthy diet and low phy-
sical activity both contribute to the appearance of dysli-
pidemia, but blood lipid profile is also highly heritable.
In addition to several mendelian forms of hyperlipemia
and hypertriglyceridemia, dyslipidemia is commonly a
complex disease or group of diseases with an estimated
heritability ranging from 25 to 80% [1]. A recent study
performed in 1,275 coronary artery disease patients
derived from the Regensburg Myocardial Infarction
Family Study has described heritabilities of 27-48% for
HDL cholesterol and 21-44% for LDL cholesterol [2].
The genetic variation in genes such as lipoprotein lipase
(LPL), hepatic lipase (LIPC), the LDL receptor (LDLR),
the ABCA1 transporter or diverse apolipoproteins, has
been found to influence blood lipid levels [3-8]. Lately, the
rapid spread of genome-wide association studies has
allowed not only the confirmation of previously described
associations, but also the identification of many quantita-
tive trait loci (QTL) for lipid levels across the genome
[9-15]. One of these loci has been recently reported for
HDL [16] and involves the WW-domain-containing oxi-
doreductase (WWOX) gene (MIM 605131). WWOX gene
is a large gene spanning about 1.1 Mb and located within
a region previously linked to HDL and familial combined
hyperlipidemia (FCHL), a hereditary disorder character-
ized by the elevation of both cholesterol and triglycerides
(TGs) in the blood [17-21]. WWOX encodes a protein
which contains 2 WW domains and a short-chain dehy-
drogenase/reductase domain (SRD). The highest normal
expression of this gene is detected in hormonally regulated
tissues such as testis, ovary, and prostate [22]. This expres-
sion pattern and the presence of an SRD domain suggest a
role for this gene in steroid metabolism. In fact, WWOX
is implicated in tumorigenesis [23-25], a pathological pro-
cess highly dependent on cholesterol metabolism. In fact,
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mia and hypocholesterolemia among other metabolic dis-
turbances [26]. A recent report by Vasan et al. [27]
associated the rs2059238 polymorphism, located at intron
5, with left ventricular wall thickness in individuals with
coronary artery disease (CAD).
To assess the effect of this gene in our population, we
have analysed the WWOX gene region for association
with TGs, HDL and TG/HDL ratio. The TG and HDL
levels are inversely correlated and their metabolism are
closely interrelated. Therefore, the TG/HDL ratio has
been suggested to be a powerful estimator of cardiovas-
cular disease risk [20,28]. We have analysed for associa-
tion with HDL, TG and TG/HDL, 1045 polymorphisms
genotyped from the Affymetrix 250 k NspI assay or
imputed with MACH 1 software using CEU HapMap
phased haplotype data [29].
Methods
Study design
This study comprises 801 non related Caucasian men
(n = 433, 54.05%) and women (n = 368, 45.95%) who
were recruited by a simple random sampling approach
from a cross-sectional population-based epidemiological
survey in Spain, aimed at investigating the prevalence of
anthropometric and physiological parameters related to
obesity and other components of MS [30,31]. Partici-
pants with previous diagnosis of type 1 diabetes were
excluded from the study.
All participants gave their written consent to partici-
pate in the study. The study protocol was approved by
the Ethics Committee of the Hospital Clínico San Carlos
of Madrid.
Measurements
Biochemical determinations
After an overnight fasting period, 20 ml of blood were
obtained from an antecubital vein without compression.
HDL and TG levels were determined by enzymatic
methods using commercial kits from Boehringer
Mannheim.
Genotypes
G e n o t y p i cd a t aw e r ed e r i v e df r o mag e n o m ew i d es c a n
performed with the 250 k NspI Affymetrix chip. Geno-
typing was done according to manufacturer’s
instructions.
Genetic quality control
Of the 253 polymorphism included in the Affymetrix
chip located at the WWOX genomic region (transcribed
region ± 2 kb), only 175 passed the quality control fil-
tering (at least 90% of individuals genotyped, minor
allele frequency (MAF) ≥ 0.05, and Hardy-Weinberg
equilibrium p > 0.05).
Statistical analysis
To compare our results with those previously published,
the 175 genotyped SNPs were used to impute untyped
polymorphism in the region using MACH 1 software
(http://www.sph.umich.edu/csg/abecasis/MACH) [29]
and CEU HapMap phased haplotypic data (http://www.
HapMap.org), since no significant differences were
observed between the Spanish and the HapMap popula-
tions (Additional files 1-2). According to the software
recommendations, only those SNPs with a r
2 >0 . 3 0w e r e
selected for the association analysis (870 polymorphisms).
Quality metrics for imputed genotypes are included in
Additional file 3. Finally, 1045 SNPs (151 directly geno-
typed and 894 imputed, all of them with MAF ≥ 0.10)
were analysed for association with HDL, TGs and HDL/
TG ratio using the linear regression procedure included
in the PLINK software [32]. 39 individuals under lipid
lowering medications were excluded from the genetic
association analyses. All the studies were adjusted by sex,
age, BMI, smoking (defined as present or past history of
smoking of at least five cigarettes per day for a minimum
of 5 years), alcohol consumption (defined as a daily
intake of more than 1 drink, equivalent to 10 g of pure
ethanol), and physical activity (physical activity was
defined as light or moderate activity for a minimum of 60
minutes per session at least three times a week). Empiri-
cal p values were obtained using the adaptative permuta-
tion method implemented in PLINK [32]. We have not
applied multiple comparison correction because we con-
sider it over-conservative for the replication of a pre-
viously described gene specially given that most
g e n o t y p e sa n a l y s e di nt h i sr e p o r ta r ed e r i v e df r o ma
small number of observed genotypes; a p value under
0.05 is interpreted as significant.
Linkage disequilibrium (LD) patterns at the WWOX
gene were analysed using Haploview software [33].
For haplotypic association analysis, we have also
employed PLINK v1.06 software [32]. Only haplotypes
with a population frequency over 5% were retained for
analysis.
Results
The characteristics of the study population are described
in Table 1.
For all the traits analysed, we have identified four
regions displaying clustering of positive signals (Additional
files 4, 5, 6, 7). They have been numbered on the basis of
their chromosomal positions from 5’ to 3’ (Figure 1):
region 1 from 76,689,775 to 76,716,533 bp (NCBI36/
hg18), region 2 from 77,433,428 to 77,441,867 bp
(NCBI36/hg18), region 3 from 77,538,855 to 77,563,088
bp (NCBI36/hg18), and region 4 from 77,605,536 to
77,620,657 bp (NCBI36/hg18). The complete list of the
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online (Additional files 8, 9, 10).
For HDL levels, two regions concentrate the positive sig-
nals, both of them in the WWOX gene intron 8 (Figure 1A
and Additional file 8). The first of them, comprises linked
SNPs in the region 77,433,428 - 77,441,867 bp (rs7405423-
rs4145518, region 2); the adjacent LD block (77,442,683-
77,457,346 bp, rs8060856-rs2656634), partially linked with
it (D’ = 0.92, Additional file 5), also shows associated mar-
kers. The strongest associations in the region were
observed for the rs4888865 (p = 0.006, b =0 . 9 6 )a n dt h e
rs4145518 (p = 0.007, b = 1.03) polymorphisms. The sec-
ond associated region, also in the 8
th intron, is distal to the
previous one (77,538,855-77,563,088 bp, region 3) and
comprises a large LD block of 42 markers (rs11643794-
rs1110894, Additional file 6) of which the rs2047927
showed the highest significance (p = 0.003, b =- 2 . 2 5 ) .
For TG quantitative association analysis, again two
regions in the intron 8 showed clustering of positive sig-
nals (Figure 1b and Additional file 9). One of these
regions was the same LD block at the region 77,433,428 -
77,441,867 bp associated with HDL (region 2), but the
signal was limited in this case to the seven first highly
linked markers (rs7405423-rs7501409, D’ = 1). The other
associated region in intron 8 extends from 77,605,536
to 77,620,657 bp (rs12598471-rs2550698, region 4,
Additional file 7), showing a peak at the rs11645630
(p = 0.002, b = -11.14). However, the highest signals in
this study are located at 76,689,775-76,716,533 bp
(rs10220974-rs1076514, region 1, Additional file 4), a
broad region that extends from the promoter to the 4
th
intron, with the largest association at rs11645006
(p = 0.0002, b = -13.81).
In the association study of the TG/HDL index, regions
1 (from 76,689,775 to 76,716,533 bp, promoter region)
and 2 (intron 8, from 77,433,428 to 77,441,867 bp) hud-
dle associated SNPs (Figure 1C and Additional file 10).
For the region 1, that is associated with TGs but not
with HDL, p values are smaller than those obtained for
TGs. On the other hand, in the region 2, which is
associated with both HDL and TGs, the significance is
increased with respect to the individual phenotypes.
Additionally, four markers of those included in region 4
(intron 8, from 77,605,536 to 77,620,657 bp) exceed the
0.05 p value threshold.
Haplotypic analysis
We have also performed a haplotypic association analy-
sis in the regions associated in the genotypic study
(Table 2). The global haplotypic effect at region 1
(76,689,775-76,716,533 bp) was significant for all the
traits analysed (0.0029 ≤ p ≤ 0.0180), despite that allelic
analysis did not show any associated marker with HDL.
For region 2 (77,433,428 - 77,441,867 bp), only HDL
was not significant. For regions 3 (77,538,855-77,563,088
bp) and 4 (77,605,536-77,620,657 bp), only the analysis
of TGs at region 4 was significant. Selection of tag SNPs
did not improve the results of the association analysis
(data not shown).
Discussion
We have reported association of four WWOX gene
regions with HDL and TG levels. One of them is located
at the 5’ end of the gene, from the promoter to the intron
4 (region 1) whereas the remaining regions are placed at
the intron 8 of the gene, a region previously associated
with HDL levels by Lee et a. [16]. Haplotypic analysis
pointed out that the allelic combinations at region 1 sig-
n i f i c a n t l ym o d i f yH D L ,T Gl e v e l sa n dt h eT G / H D L
index, despite that no individual SNP associations were
found for HDL in this region. Moreover, none of the
intron 8 regions are associated with HDL in the haploty-
pic analysis, although region 2 shows a trend for associa-
tion (p = 0.07). Regions 2 and 4 are associated with TG
levels and only region 2 with the TG/HDL index.
Our results suggest that the WWOX gene is associated
with HDL and TGs levels in our study population. From
a functional point of view, the 5’ region of the gene with
both TG and HDL is highly interesting, since includes
regulatory regions of the gene and two 44 bp insertion/
Table 1 Characteristics of the study population
All
N = 801
Men
N = 433
Women
N = 368
Men vs women
P value
Age (years) 51.90 (8.81) 51.57 (9.24) 52.30 (8.28) 0.242
BMI (kg/m2) 27.44 (4.29) 27.11 (3.71) 27.84 (4.87) 0.017
Triglycerides (mg/dl) 104.81 (73.23) 116.36 (83.38) 91.21 (56.26) 1.09 × 10
-6
HDL (mg/dl) 50.57 (20.78) 46.08 (19.09) 55.86 (21.45) 1.72 × 10
-11
Smokers (%) 28.6% 42.5% 12.2% 1.34 × 10
-14
Alcohol consumers (%) 66.0% 83.4% 45.7% 2.97 × 10
-14
Physical active (%) 46.3% 45.3% 47.6% 0.523
For quantitative traits, values represent means and, in brackets, standard deviations (SD). For the statistical differences p values (Anova test for quantitative traits
and exact test for dichotomic traits) are given.
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Page 3 of 8Figure 1 Graphical representation of the association analysis of the WWOX gene with HDL (Figure 1A), triglycerides (Figure 1B) and
TG/HDL index (Figure 1C). Dots symbolize the logarithm of the p value at each marker. In the top of the Figure a scaled representation of the
WWOX gene structure is shown. Shaded numbered zones point out the regions referred in the text as regions 1-4.
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Page 4 of 8Table 2 Haplotypic analysis at the four WWOX regions selected in the genotypic analysis
HAPLOTYPE FREQ. TGs HDL TGs/HDL
REGION 1 CTTCCTCCCGCGCAGA 0.14 (-ref) (-ref) (-ref)
TTCGATCTTCGATGGG 0.12 11.44
(0.09; 22.80)
0.38
(-2.03; 2.78)
0.28
(-0.05; 0.59)
CCTGAGTTTCGACAGG 0.11 10.05
(-1.96; 22.10)
-2.14
(-4.68; 0.41)
0.34
(0.01; 0.68)
CCTGAGTTTCGATGGG 0.17 15.32
(5.27; 25.40)
0.41
(-1.72; 2.54)
0.39
(0.10; 0.67)
CTCGATTTTCCGCACA 0.09 2.85
(-10.30; 16.00)
0.60
(-2.18; 3.38)
0.003
(-0.37; 0.38)
CCTGAGTTTCCACAGG 0.07 7.82
(-6.54; 22.20)
4.24
(1.2; 7.28)
0.03
(-0.38; 0.43)
CTTCCTCTTCCATAGG 0.05 10.54
(-5.77; 27.00)
2.73
(-0.75; 6.19)
0.23
(-0.23; 0.69)
CTTCCTCTTCCGCACA 0.07 -15.76
(-30.20;-1.29)
2.04
(-1.02; 5.11)
-0.42
(-0.83; -0.01)
GLOBAL HAPLOTYPIC EFFECT F = 3.13
p=0.003
F = 2.435
p=0.018
F = 2.836
p=0.006
REGION 2 TGACAAGACATG 0.09 (-ref) (-ref) (-ref)
CATAAAGAGGTA 0.07 1.50
(-13.50; 16.50)
-2.62
(-5.79; 0.56)
0.09
(-0.33; 0.52)
CATACGCGGGTA 0.52 12.54
(3.34; 21.70)
-2.43
(-4.37; -0.48)
0.41
(0.15; 0.66)
CATACGCGGGCA 0.19 8.36
(-2.86; 19.60)
-3.33
(-5.7; -0.95)
0.31
(-0.01; 0.62)
CATACGCGCATA 0.05 20.08
(3.23; 36.90)
-1.81
(-5.37; 1.76)
0.67
(0.20; 1.15)
GLOBAL HAPLOTYPIC EFFECT F = 2.72
p=0.028
F = 2.17
p = 0.070
F = 3.50
p=0.007
REGION 3 GACGCTGCACTAGCGATCATTAGTACCAGACATGACAGCCCGC 0.28 (-ref) (-ref) (-ref)
ATGTTCAGAGTAAGCGAGGTCACCGCGGCGGCCAGGGATATAT 0.31 -3.62
(-11.30; 4.04)
0.72
(-0.89; 2.34)
-0.13
(-0.34; 0.09)
GAGGTTGGGCAGGCCATCACTGCTACCAGACCTGAGAACACAC 0.07 -12.22
(-25.10; 0.67)
-2.07
(-4.78; 0.65)
-0.26
(-0.62; 0.11)
GLOBAL HAPLOTYPIC EFFECT F = 1.89
p = 0.151
F = 1.81
p = 0.165
F = 1.35
p = 0.261
REGION 4 GCTCTCCCGAAGGCCAGAGAACACCTAGACGATT 0.12 (-ref) (-ref) (-ref)
GCTCTCCCTAGGGTAGAAAGCATTCCCCAAGATT 0.06 -11.44
(-27.80; 4.88)
0.54
(-2.93; 4.02)
-0.32
(-0.79; 0.14)
GTACGAGCGAAGGCCAGAGAACACCTAGACGATT 0.18 6.45
(-3.59; 16.50)
-1.09
(-3.24; 1.04)
0.20
(-0.09; 0.48)
GTACGAGCTAGGGTAGAAAGCATTCCCCAAGATT 0.18 -6.28
(-15.4; 2.84)
-0.30
(-2.24; 1.64)
-0.09
(-0.35; 0.17)
GTACGAGCGGGAACCGGGAAACACCCACACAATT 0.07 11.58
(-1.97; 25.10)
-1.02
(-3.90; 1.87)
0.28
(-0.11; 0.66)
GLOBAL HAPLOTYPIC EFFECT F = 2.61
p=0.0347
F = 0.43
p = 0.786
F = 1.99
p = 0.0939
Region 1 (Chr.16: 76,689,775-76,716,533 bp): rs10220947, rs4887935, rs7192129, rs12931172, rs8045450, rs2287973, rs2287972, rs16947127, rs16947129,
rs12917833, rs10492874, rs11645006, rs2042356, rs1079569, rs12920698, rs1076514.
Region 2 (Chr.16: 77,433,428 - 77,441,867 bp): rs7405423, rs7405283, rs9922613, rs4888865, rs6420411, rs1543296, rs7498176, rs7501409, rs12447303, rs7190122,
rs11643930, rs4145518.
Region 3 (Chr.16: 77,538,855-77,563,088 bp): rs11643794, rs11642227, rs10871357, rs4888887, rs1995549, rs8063186, rs11648482, rs7205567, rs16949032,
rs17709129, rs17709147, rs17635945, rs11150119, rs9319530, rs13334115, rs10871358, rs12596756, rs12925319, rs16949036, rs12447067, rs9941223, rs7189021,
rs17636170, rs8052880, rs4600477, rs4888888, rs4888889, rs8052893, rs11150120, rs13339083, rs4888892, rs13330742, rs16944152, rs2047927, rs5024396,
rs17636262, rs2062900, rs8057659, rs12716865, rs1467067, rs11860206, rs1110891, rs1110894.
Region 4 (Chr.16: 77,605,536 - 77,620,657 bp): rs12598471, rs2550725, rs1862841, rs16949214, rs2550724, rs12447246, rs2550723, rs16949222, rs2113305,
rs7185820, rs8064141, rs16949238, rs16949240, rs2656653, rs2550718, rs2550717, rs2550716, rs16949251, rs8047597, rs2550711, rs8047300, rs2550710, rs7199119,
rs1808447, rs905781, rs8053936, rs2550702, rs2550701, rs2656649, rs11645630, rs16949276, rs2656647, rs2656646, rs2550698.
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have been eight different mRNAs described (7 alterna-
tively spliced variants and 1 unspliced form) and three
probable alternative promoters [34]. Of eight transcripts,
six spliced and the unspliced mRNAs putatively encode
good proteins. It is tempting to speculate that genetic
variations in this region could modify the expression of
the WWOX gene. Functional analyses are needed to
answer this hypothesis.
The second region identified in this study is, of the
three regions identified in intron 8, the one nearest to
the 5’ boundary of this uncoding region. It is associated
with all the traits analysed, although for HDL, it didn’t
reach the statistical significance threshold. This region is
in high LD with the rs2548861 polymorphism associated
by Lee et al. (D’ = 0.72), which is located upstream of
this region at approximately 200 kb.
Two other regions of the large intron 8 (around 800
kb long) display clustering of associated SNPs with HDL
or TG. The global haplotypic analyses for these two
regions were not significant, indicating that the observed
associations in the genotypic analysis seem to be related
with individual polymorphic effects rather than to hap-
lotypic blocks.
Genotype imputation methods are now being commonly
used in the analysis of genome-wide association studies.
Imputation enables researchers to pool and/or compare
data between studies conducted using different SNP sets.
It is also possible to fine map associated regions. Imputa-
tion methods work by combining a reference panel of
individuals genotyped at a dense set of polymorphisms
with a study sample collected from a genetically similar
population and genotyped at a subset of these SNPs.
Usually, HapMap panels are employed as the reference
sample. It has raised the question about how well these
panels represent the genetic variation in other populations
that, for historical and demographic reasons, are more dis-
tant from the reference population. Two recent papers
have analyzed the genomic diversity in European popula-
tions and revealed that the level of genetic differentiation
within Europe is small [35] while the complex origin of
the Spanish population is reflected in a greater haplotypic
diversity than Northern/Western Europeans, although this
divergence is not statistically significant [36]. These
reports are in accordance with our observation that the
Spanish population is largely homogeneous and in general
similar, to the CEU HapMap sample in terms of MAF and
LD patterns, notwithstanding that our population has
more blocks and smaller on average [37]. Specifically at
the WWOX region, no significant differences were
observed between the Spanish and the CEU HapMap sam-
ple (Additional files 1-2). Regarding accuracy of imputa-
t i o n ,w eh a v er e c e n t l yi m p u t e dt h ec o m p l e t eg e n o m e
using the 250 k NspI chip information and CEU HapMap
sample with an overall concordance of 96.7% between the
genotyped and imputed genotypes revealed by the use of
the mask function. These findings are in accordance with
the results presented by Huang et al. [38] that described
high imputation accuracy for all the European populations
examined (including a Spanish sample) with the CEU
HapMap reference panel. Another supporting argument
for the validity of the imputed genotypes is that the pro-
portion of genotyped:imputed SNPs is 1:6. The associated
SNPs are an admixture of both of them in approximately
t h es a m ep r o p o r t i o n :1 : 8 . 7f o rH D L ,1 : 6 . 6f o rT G sa n d
1:8.4 for TG/HDL, with p values greater than 0.5 for the
comparison of the distribution of associated/not associated
SNPs in both genotyped and imputed classes.
In our study, we failed to replicate the association of the
rs2548861 with HDL. This polymorphism has been
imputed in our study population, and inaccurate imputa-
tion could be the cause for the absence of association,
although it is unlikely for the reasons exposed above. We
have estimated the effect size (ES) of this SNP in our study
using the same method employed by Lee based on the t
statistics (ES = t × sqrt [[n0 + n1]/[n0 × n1]], ni = number
of participants coded as i), that represents the proportion
of one-standard-deviation change in HDL. In our study
population, the ES for the rs2548861 is -0.08, exactly the
same raw score obtained by Lee et al. for the METSIM
cohort, which includes more than 4,000 males. We esti-
mate that our study is underpowered for SNPs with effect
sizes below 0.14, so we can not rule out power issues.
However, in the report by Lee et al [16] the effect of the
rs2548861 was identified in familial cases of dyslipidemia
and validated in two large population-based samples of
Finnish samples, but the authors also failed to replicate
this association in three GWAS dataset: the Diabetes
Genetics Initiative (DGI) (1,464 cases of type 2 diabetes
and 1,467 non-diabetic control individuals from Scandina-
via), the Finland-United States Investigation of NIDDM
Genetics (FUSION, 1,161 Finnish type 2 diabetes cases,
1,174 normal glucose tolerant controls, and 122 offspring
of case/control pairs) and the Sardinia study of aging-
associated variables cohorts (4,305 related individuals). Lee
et al. pointed out that part of the initial linkage signal
remains unexplained by rs2548861, suggesting that addi-
tional variants in the WWOX region influence lipid levels.
In fact, the rs2667590 polymorphism, located also in the
intron 8 but not linked to the rs2548861 polymorphism,
has been also associated with HDL levels [12].
In our study, a new region in the WWOX gene, the pro-
moter, is shown to be associated with both HDL and TG
levels, spanning the susceptibility region to the proximal
region of the long arm of chromosome 16. 10 Mbp away
from the WWOX gene, at 16q22, several recent reports
have identified different polymorphisms at the lecithin-
cholesterol acyltransferase (LCAT) gene in association
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Page 6 of 8with HDL [12-15]. It has been recently reported the exis-
tence of synthetic associations, that is, combinations of
several low frequency variants across large regions of the
genome. These synthetic associations can span up to 10
Mb and encompass several LD blocks [39,40]. It is then
possible that the WWOX and the LCAT regions are com-
ponents of the same synthetic haplotype which contributes
to the regulation of blood lipid levels.
The work presented in this article, has identified new
putative SNPs associated, not only with HDL, but also
with triglycerides and the TG/HDL index, a powerful
estimator or cardiovascular risk. In addition to the pre-
viously described intron 8, we have identified the pro-
moter region as a new region influencing both HDL and
TG levels. We cannot rule out that some of the
observed associations could have arisen by chance, rea-
son why additional, independent replications are needed.
Conclusions
In conclusion, the information derived from the genome
wide genotyping combined with that provided for the
imputation procedure, has allowed us to fine map the
WWOX region. We agree with Lee et al. [16] on the
relevance of WWOX intron 8 in HDL and we extend it
to TG levels. In addition, we have identified the 5’
region of the gene as another putative source of HDL
and TG variance at least in this Spanish sample. The
WWOX gene is therefore a promising target for future
research in cardiovascular diseases and risk factors.
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